Related references
Note: Only part of the references are listed.Circulating free tumor DNA in non-small cell lung cancer (NSCLC): clinical application and future perspectives
Guillaume Herbreteau et al.
JOURNAL OF THORACIC DISEASE (2019)
Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology
Neal I. Lindeman et al.
ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2018)
Circulating Tumor DNA Analysis in Patients With Cancer: American Society of Clinical Oncology and College of American Pathologists Joint Review
Jason D. Merker et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Correlation between progression-free survival, tumor burden, and circulating tumor DNA in the initial diagnosis of advanced-stage EGFR-mutated non-small cell lung cancer
Yunkyoung Lee et al.
THORACIC CANCER (2018)
Overview on Clinical Relevance of Intra-Tumor Heterogeneity
Giorgio Stanta et al.
FRONTIERS IN MEDICINE (2018)
Comprehensive Analysis of the Discordance of EGFR Mutation Status between Tumor Tissues and Matched Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer
Rui Wan et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Application of Plasma Genotyping Technologies in Non-Small Cell Lung Cancer: A Practical Review
Adrian G. Sacher et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution
Christopher Abbosh et al.
NATURE (2017)
PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer
Ji-Youn Han et al.
BMC CANCER (2016)
Circulating Tumor DNA Detection in Early-Stage Non-Small Cell Lung Cancer Patients by Targeted Sequencing
Ke-Zhong Chen et al.
SCIENTIFIC REPORTS (2016)
Circulating tumor DNA detection in lung cancer patients before and after surgery
Nannan Guo et al.
SCIENTIFIC REPORTS (2016)
Prospective Study of Repeated Biopsy Feasibility and Acquired Resistance at Disease Progression in Patients With Advanced EGFR Mutant Lung Cancer Treated With Erlotinib in a Phase 2 Trial
Amanda J. Redig et al.
JAMA ONCOLOGY (2016)
Diagnostic Accuracy of Noninvasive Genotyping of EGFR in Lung Cancer Patients by Deep Sequencing of Plasma Cell-Free DNA
Junji Uchida et al.
CLINICAL CHEMISTRY (2015)
First-line gefitinib in Caucasian EGFR mutation-positive NSCLC patients: a phase-IV, open-label, single-arm study
J-Y Douillard et al.
BRITISH JOURNAL OF CANCER (2014)
Intratumoral heterogeneity of KRAS mutation is rare in non-small-cell lung cancer
Winfried H. Alsdorf et al.
EXPERIMENTAL AND MOLECULAR PATHOLOGY (2013)
Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I-IV Non-Small Cell Lung Cancer Patients
Xiao Zhao et al.
RESPIRATION (2013)
Heterogeneous Distribution of EGFR Mutations Is Extremely Rare in Lung Adenocarcinoma
Yasushi Yatabe et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cell-free Tumor DNA in Blood Plasma As a Marker for Circulating Tumor Cells in Prostate Cancer
Heidi Schwarzenbach et al.
CLINICAL CANCER RESEARCH (2009)
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib
W Pao et al.
PLOS MEDICINE (2005)
EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib
W Pao et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
About the possible origin and mechanism of circulating DNA - Apoptosis and active DNA release
M Stroun et al.
CLINICA CHIMICA ACTA (2001)
Horizontal transfer of oncogenes by uptake of apoptotic bodies
A Bergsmedh et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Share Paper
